Search - tctmd.com

Displaying 581 - 600 of 963

Sort: Relevancy | Date

News Daily News

Continuing Anticoagulation During TAVR: New Data Offer a Glimpse of What Works

Shelley Wood

April 16, 2019

News Conference News ACC 2019

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

Shelley Wood

April 05, 2019

News Daily News

First US Consensus Statement on PFO Closure Addresses Volume Requirements, Quality Measurements

Yael L. Maxwell

April 01, 2019

Presentation SIF 2019

Unresolved Issues: Cerebral Embolic Protection Use Selectively!

Presenter: Steven J Yakubov

March 30, 2019

News Daily News

Survival Better With Early AVR for Severe Asymptomatic Aortic Stenosis, Says Retrospective Study

L.A. McKeown

March 29, 2019

Presentation CIT 2019

Cerebral Protection in TAVR

Presenter: Alexandra Lansky

March 28, 2019

News Daily News

CMS Coverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

Michael O'Riordan

March 27, 2019

Presentation SIF 2019

Closing a Hole in the Heart

Presenter: David G. Rizik

March 27, 2019

Presentation SIF 2019

Left Atrial Appendage Closure is an Under-Utilized Therapy

Presenter: Brij Maini

March 27, 2019

News Conference News ACC 2019

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

Yael L. Maxwell

March 17, 2019

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

News Industry News

FDA approves new indication for valve repair device to treat certain heart failure patients with mitral regurgitation

March 14, 2019

News Daily News

HF Admissions Decline, Non-CV Hospitalizations Rise After TAVR

L.A. McKeown

March 13, 2019

News Daily News

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

Todd Neale

March 12, 2019

News Conference News ACC 2019

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Shelley Wood

March 11, 2019

News Daily News

Signal of Aortic Stenosis Risk With Celecoxib

Michael O'Riordan

March 05, 2019

News Conference News CRT 2019

BASILICA Leaflet Laceration Before TAVR Helps Prevent Coronary Obstruction

Yael L. Maxwell

March 04, 2019

News Conference News CRT 2019

One-Year Data on Low-Risk TAVR Continue to Show Good Safety: LRT

Yael L. Maxwell

March 04, 2019

News Daily News

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

Yael L. Maxwell

March 01, 2019

News Daily News

New Leaflet Thrombosis After TAVR Seen Out to 3 Years: OCEAN-TAVI

Shelley Wood

February 19, 2019

Advertisement

Continuing Anticoagulation During TAVR: New Data Offer a Glimpse of What Works

My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay

First US Consensus Statement on PFO Closure Addresses Volume Requirements, Quality Measurements

Unresolved Issues: Cerebral Embolic Protection Use Selectively!

Survival Better With Early AVR for Severe Asymptomatic Aortic Stenosis, Says Retrospective Study

Cerebral Protection in TAVR

CMS Coverage Plan Keeps Volume Requirements for Existing TAVR Programs but Lowers Bar for New Centers

Closing a Hole in the Heart

Left Atrial Appendage Closure is an Under-Utilized Therapy

TAVR in Bicuspid Aortic Stenosis Safe, Feasible in Selected Real-World Patients

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

FDA approves new indication for valve repair device to treat certain heart failure patients with mitral regurgitation

HF Admissions Decline, Non-CV Hospitalizations Rise After TAVR

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend

Signal of Aortic Stenosis Risk With Celecoxib

BASILICA Leaflet Laceration Before TAVR Helps Prevent Coronary Obstruction

One-Year Data on Low-Risk TAVR Continue to Show Good Safety: LRT

Lotus Maintains Good Safety, Efficacy at 2 Years, Though Questions Persist Over Permanent Pacing

New Leaflet Thrombosis After TAVR Seen Out to 3 Years: OCEAN-TAVI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content